普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析

doi:10.19438/j.cjoms.2017.03.015

中国口腔颌面外科杂志 ›› 2017, Vol. 15 ›› Issue (3): 264-267.doi: 10.19438/j.cjoms.2017.03.015

普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析

程沫沙，张凯驰，王绪凯

中国医科大学口腔医学院口腔颌面外科，辽宁省口腔医学研究所口腔颌面外科研究室，辽宁沈阳 110002

收稿日期:2016-06-30 修回日期:2016-09-03 出版日期:2017-05-20 发布日期:2017-06-09
作者简介:程沫沙（1990-），女，硕士，E-mail：18640198343@163.com
基金资助:
王绪凯，E-mail：wangxukai757892@sina.com

Propranolol in the treatment of ulcerated infantile hemangiomas: a clinical analysis of 18 cases

CHENG Mo-sha, ZHANG Kai-chi, WANG Xu-kai.

Department of Oral and Maxillofacial Surgery, School of Stomatology, China Medical University, Liaoning Institute of Dental Research. Shenyang 110002, Liaoning Province, China

Received:2016-06-30 Revised:2016-09-03 Online:2017-05-20 Published:2017-06-09

摘要/Abstract

摘要： 目的：评价普萘洛尔治疗溃疡性婴幼儿血管瘤的临床疗效和安全性。方法：选择2009年6月—2015年10月于中国医科大学附属口腔医院收治的18例并发溃疡的婴幼儿血管瘤患者，其中男7例，女11例。所有患儿均口服普萘洛尔，按1.0～1.5 mg/kg给药，每天1次顿服，连续给药3～12个月。每周复诊，至溃疡面完全愈合后改为每月复诊。动态观察并记录血管瘤大小、质地和颜色变化，溃疡面愈合情况、愈合时间，治疗结束或瘤体消退后有无瘢痕遗留。通过治疗期间出现的不良反应进行安全性评价。结果：18例患儿溃疡愈合时间为2~9周，平均3.96周；治疗时间为3~12个月，平均8个月；随诊时间8~24个月，平均17.8个月。2例患者遗留瘢痕。发现心率减慢、腹泻、溢奶、睡眠改变等不良反应，均未做特殊处理，未发生严重全身或局部不良反应。结论：口服普萘洛尔治疗溃疡性婴幼儿血管瘤能使溃疡面在短期内愈合，使血管瘤明显缩小，不良反应轻微，可作为治疗溃疡性婴幼儿血管瘤的首选方法。

关键词: 婴幼儿血管瘤, 溃疡, 普萘洛尔, β受体阻滞剂

Abstract: PURPOSE: To evaluate the clinical efficacy and safety of oral propranolol in the management of ulcerated infantile hemangiomas (IHs). METHODS: Oral propranolol was administered to 18 infants with hemangioma complicated by ulceration at a dose of 1-1.5 mg/kg of body weight per day. The treatment was continued for 3-12 months. Weekly visits were required until the ulcerations were healed, then changed to monthly visits. The therapeutic outcomes and safety were assessed by the changes of colors, size of tumor, healing of the ulcers and adverse effects throughout the course of treatment. RESULTS: Among 18 patients, ulcerations were healed within 2-7 weeks. The mean therapeutic duration was 8 months ranging from 3 to 12 months. Two of them left scars in the end of treatment. The main adverse effects were bradycardia, diarrhea, milk regurgitation, sleep disturbance, which resolved without special management. No major adverse effects were observed. CONCLUSIONS: Oral propranolol for ulcerated IHs can make the ulcer heal in a short time, and can significantly reduce hemangioma size; the adverse reactions were minimal.

Key words: Infantile hemangioma, Ulceration, Propranolol, Beta blocker

中图分类号:

R739.8

程沫沙，张凯驰，王绪凯. 普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析[J]. 中国口腔颌面外科杂志, 2017, 15(3): 264-267.

CHENG Mo-sha, ZHANG Kai-chi, WANG Xu-kai.. Propranolol in the treatment of ulcerated infantile hemangiomas: a clinical analysis of 18 cases[J]. China J Oral Maxillofac Surg, 2017, 15(3): 264-267.

参考文献

[1] 中华口腔医学会口腔颌面外科专业委员会脉管性疾病学组.口腔颌面部血管瘤治疗指南[J]. 中国口腔颌面外科杂志, 2011, 9(1): 61-67.
[2] Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature [J]. Pediatr Dermatol, 2008, 25(2): 168-173.
[3] 孙桦梁, 席善龙, 王绪凯, 等. 口服普萘洛尔治疗婴幼儿腮腺区血管瘤的疗效观察 [J]. 口腔颌面外科杂志, 2013, 23(6): 463-466.
[4] Wananukul S, Chatproedprai S. Ulcerated hemangiomas: clinical features and management [J]. J Med Assoc Thai, 2002, 85(11): 1220-1225.
[5] Shin HT, Orlow SJ, Chang MW. Ulcerated hemangioma of infancy: a retrospective review of 47 patients [J]. Br J Dermatol, 2007, 156(5): 1050-1052.
[6] 马刚, 林晓曦. 溃疡性血管瘤的研究进展 [J]. 组织工程与重建外科杂志, 2011, 7(6): 350-353.
[7] Waner M, Suen JY. Hemangiomas and vascular malformations of the head and neck [M]. New York: Wiley-liss Inc., 1999: 3, 57-58, 93-169.
[8] Li G, Xu DP, Cheng C, et al. Oral propranolol for parotid infantile hemangiomas[J]. J Craniofac Surg, 2015, 26(2): 438-440.
[9] Greene AK, Couto RA. Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol [J]. Plast Reconstr Surg, 2011, 128(3): 743-752.
[10] Bauland CG, Lüning TH, Smit JM, et al. Untreated hemangiomas: growth pattern and residual lesions [J]. Plast Reconstr Surg, 2011, 127(4): 1643-1648.
[11] David LR, Malek MM, Argenta LC. Efficacy of pulse dye laser therapy for the treatment of ulcerated hemangiomas: a review of 78 patients [J]. Br J Plast Surg, 2003, 56(4): 317-327.
[12] Thomas RF, Hornung RL, Manning SC, et al. Hemangiomas of infancy: treatment of ulceration in the head and neck [J]. Arch Facial Plast Surg, 2005, 7(5): 312- 315.
[13] Chamlin SL, Haggstrom AN, Drolet BA, et al. Multicenter prospective study of ulcerated hemangiomas [J]. J Pediatr, 2007, 151(6): 684-689.
[14] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy [J]. N Engl J Med, 2008, 358(24): 2649-2651.
[15] Li G, Xu DP, Tong S, et al. Oral propranolol with topical timolol maleate therapy for mixed infantile hemangiomas in oral and maxillofacial regions: a randomized clinical trial [J]. J Craniofac Surg, 2016, 27(1): 56-60.
[16] 宫贺, 徐大朋, 王绪凯, 等. 0.5%马来酸噻吗洛尔联合普萘洛尔治疗婴幼儿血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2014, 12(5): 441- 445.
[17] Chisholm KM, Chang KW, Truong MT, et al. β-Adrenergic receptor expression in vascular tumors [J]. Mod Pathol, 2012, 25(11): 1446-1451.
[18] 薛雷. 血管瘤发病机制及治疗前景展望 [J]. 中国实用口腔科杂志, 2010, 3(10): 632- 635.

普萘洛尔治疗溃疡性婴幼儿血管瘤18例临床分析

Propranolol in the treatment of ulcerated infantile hemangiomas: a clinical analysis of 18 cases

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郑家伟, 王绪凯, 秦中平, 范新东, 李凯, 杨耀武, 霍然, 刘少华, 赵吉宏, 汪小勇, 周德凯, 刘学键. 口服普萘洛尔治疗婴幼儿血管瘤中国专家共识（2022版）[J]. 中国口腔颌面外科杂志, 2022, 20(4): 313-319.
[2]	郑家伟, 赵泽亮, 陈启铭. 婴幼儿血管瘤循证治疗现状[J]. 中国口腔颌面外科杂志, 2022, 20(1): 7-14.
[3]	胡文月, 吕翔, 孙宇. 鼻腔气管导管固定对经鼻气管插管患者鼻部压力的影响[J]. 中国口腔颌面外科杂志, 2021, 19(4): 345-349.
[4]	王杞章, 郑家伟. 口服普萘洛尔治疗婴幼儿增殖期血管瘤:英国儿科皮肤病学会共识及临床指南[J]. 中国口腔颌面外科杂志, 2020, 18(6): 548-552.
[5]	顾达, 霍然, 徐广琪, 毕见海, 李尚滨. 局部外用β受体阻滞剂治疗婴幼儿血管瘤的临床应用研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(4): 375-380.
[6]	李红, 周昱川, 龚忠诚, 孙杨, 凌彬. 口服普萘洛尔联合外用盐酸倍他洛尔治疗8例眶周高风险婴幼儿血管瘤的疗效和安全性评价[J]. 中国口腔颌面外科杂志, 2020, 18(3): 264-268.
[7]	宋会新, 林春男, 王田友, 付兆臣. 普萘洛尔治疗婴幼儿血管瘤的作用机制研究进展[J]. 中国口腔颌面外科杂志, 2020, 18(2): 182-185.
[8]	刘学键, 刘志鹏, 武宜雷, 邰茂众. 平阳霉素新剂型瘤体内注射治疗婴幼儿血管瘤203例临床分析[J]. 中国口腔颌面外科杂志, 2019, 17(3): 247-250.
[9]	刘诗奇, 羊良慧, 陈国生, 王辉, 房芳, 廖显翔, 麦华明. β肾上腺素受体在舌癌CAL-27细胞系的表达及β受体阻滞剂对其增殖、迁移、侵袭的影响[J]. 中国口腔颌面外科杂志, 2018, 16(5): 391-396.
[10]	张凯驰, 徐大朋, 程沫沙, 王绪凯. 马来酸噻吗洛尔和普萘洛尔治疗婴幼儿表浅型血管瘤的疗效分析[J]. 中国口腔颌面外科杂志, 2017, 15(6): 529-533.
[11]	周昱川，凌彬，龚忠诚，许颖捷，陈青立. 外涂盐酸倍他洛尔滴眼液治疗7例表浅型婴幼儿血管瘤疗效观察[J]. 中国口腔颌面外科杂志, 2017, 15(5): 438-441.
[12]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 147-152.
[13]	赵志国, 潘遥, 杨东升, 张力平. 口服普萘洛尔治疗婴幼儿鼻部血管瘤临床疗效评价[J]. 中国口腔颌面外科杂志, 2017, 15(2): 161-164.
[14]	董建勇, 李凯, 岳琳琳, 李荣慧, 黄莹莹, 刘少华. 口服普萘洛尔对血管瘤患儿体格发育的近期影响[J]. 中国口腔颌面外科杂志, 2016, 14(6): 510-513.
[15]	王菲楠, 范新东. 放射性核素治疗婴幼儿血管瘤的现状[J]. 中国口腔颌面外科杂志, 2016, 14(5): 471-474.